All In Biotech

NDA 020234 · Novartis

Tegretol-Xr

Carbamazepine · Oral · Mood Stabilizer

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Mar 25, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

199

31 Phase 3, 6 recruiting

FAERS reports

65,299

56,574 serious, 5,535 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNINGS SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING...

What it is approved for

From the label in effect Aug 20, 2026.

INDICATIONS AND USAGE Epilepsy Tegretol is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of Tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by Tegretol (see PRECAUTIONS, General). Trigeminal Neuralgia Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Mechanism: Mechanism of Action Tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Tegretol greatly reduces or abolishes pain induced by stimulation of the infraorbital nerve in cats and rats. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Tegretol is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TEGRETOL-XR · CARBAMAZEPINE 200MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TEGRETOL-XR · CARBAMAZEPINE 400MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TEGRETOL-XR · CARBAMAZEPINE 100MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbamazepine" as an intervention, any sponsor and status, largest first.

All 199 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,996
  • seizure3,651
  • drug interaction3,464
  • fall2,983
  • dizziness2,824
  • toxicity to various agents2,752
  • off label use2,739
  • pyrexia2,707
  • nausea2,621
  • vomiting2,512
  • fatigue2,405
  • somnolence2,360

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,434
20051,784
20061,707
20071,643
20081,893
20092,340
20102,299
20112,508
20123,262
20132,548
20142,836
20153,456
20163,562
20173,669
20184,453
20194,159
20203,496
20213,835
20223,419
20232,917
20242,925
20252,930
20262,217

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tegretol XR (Carbamazepine)

2024 spending

$15.6M

Beneficiaries

3,976

28,016 claims

Per beneficiary

$3,918

$3.97 per unit

View as table
YearSpending
2020$17,985,076
2021$16,709,528
2022$16,478,477
2023$17,280,708
2024$15,579,313

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,597 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.